What Is Survodutide? Uses, Benefits, Safety, FDA Status, and Evidence
Medical review note: This article is for educational purposes only and does not provide medical advice. Survodutide is investigational and is not FDA-approved. Products sold online as survodutide, “research use only” survodutide, or compounded survodutide may carry safety, quality, and legal risks.
Quick answer
Survodutide is an investigational once-weekly injectable medication being developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is a dual glucagon/GLP-1 receptor agonist, meaning it activates both glucagon and glucagon-like peptide-1 receptor pathways. Survodutide is being studied for obesity, overweight, type 2 diabetes-related metabolic disease, and metabolic dysfunction-associated steatohepatitis, also called MASH. Human trials have shown meaningful weight-loss and liver-disease effects, but survodutide is not FDA-approved and is not legally available as a normal prescription medication. Online survodutide products should be treated as unapproved and potentially unsafe.
Key facts about Survodutide
| Question | Answer |
|---|---|
| What is survodutide? | An investigational once-weekly dual glucagon/GLP-1 receptor agonist. |
| Other names | BI 456906, glucagon/GLP-1 dual agonist. |
| Developer | Boehringer Ingelheim, in partnership with Zealand Pharma. |
| Drug class | Dual glucagon receptor and GLP-1 receptor agonist. |
| Main mechanism | Activates GLP-1 pathways that influence appetite and glucose regulation, plus glucagon pathways that may affect energy expenditure and liver fat metabolism. |
| FDA-approved? | No. Survodutide is investigational. |
| Main studied uses | Obesity, overweight with comorbidities, MASH, liver fibrosis, and type 2 diabetes-related metabolic disease. |
| Human evidence level | Moderate to strong clinical-trial evidence, including phase 2 data and reported phase 3 obesity results, but not FDA-approved. |
| Common side effects in trials | Gastrointestinal symptoms such as nausea, vomiting, diarrhea, constipation, and decreased appetite. |
| Sports status | Not found here as specifically named on the WADA list, but because survodutide is investigational and not approved, athletes should verify current WADA/Global DRO status before use. |
| Main safety concern | Investigational status, gastrointestinal side effects, long-term safety still being studied, and risks from unapproved online products. |
What is survodutide?
Survodutide is an investigational injectable metabolic drug candidate. It is being developed by Boehringer Ingelheim in partnership with Zealand Pharma.
Zealand Pharma describes survodutide as an investigational long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration. Boehringer Ingelheim describes survodutide as a novel glucagon/GLP-1 dual agonist being studied for obesity, overweight, and liver-related metabolic disease.
Survodutide belongs to the same broad modern obesity-drug landscape as semaglutide, tirzepatide, retatrutide, and cagrilintide, but it is mechanistically different.
| Drug | Receptor targets | Current status |
|---|---|---|
| Semaglutide | GLP-1 | FDA-approved under brands such as Ozempic, Wegovy, and Rybelsus. |
| Tirzepatide | GIP + GLP-1 | FDA-approved under brands such as Mounjaro and Zepbound. |
| Retatrutide | GIP + GLP-1 + glucagon | Investigational. |
| Cagrilintide | Amylin analog | Investigational as a standalone drug. |
| Survodutide | Glucagon + GLP-1 | Investigational. |
The key distinction:
Survodutide is not an approved medication. It is a clinical-stage investigational drug.
How does survodutide work?
Survodutide is designed to activate two hormone receptor systems:
- GLP-1 receptor
- Glucagon receptor
GLP-1 receptor activation can reduce appetite, increase satiety, support glucose regulation, and slow gastric emptying. Glucagon receptor activation may influence energy expenditure, fat metabolism, and liver-fat biology.
In plain English:
Survodutide is being studied because it combines GLP-1 appetite and metabolic effects with glucagon receptor activity that may support weight loss, body-composition changes, and liver-fat reduction.
That is why survodutide is being studied not only for obesity, but also for MASH, a serious liver disease associated with metabolic dysfunction.
But mechanism is not approval. A strong mechanism and promising clinical data do not mean a drug is already safe, approved, or legally available.
What is survodutide used for?
Survodutide is being studied for metabolic conditions, but it does not yet have an FDA-approved use.
| Use | Evidence level | What is known | What is not known |
|---|---|---|---|
| Obesity | Strong clinical-trial evidence, but investigational | Phase 2 and reported phase 3 data show meaningful body-weight reductions. | Final FDA approval, label, dosing, long-term safety, and prescribing rules are not established. |
| Overweight with comorbidities | Clinical-trial evidence | Trials include adults with overweight and obesity-related health conditions. | Approved indication, if any, depends on regulatory review. |
| MASH | Phase 2 evidence | NEJM phase 2 data showed MASH improvement without worsening fibrosis. | Long-term liver outcomes and FDA-approved liver indication are not established. |
| Liver fibrosis | Phase 2 evidence | Boehringer reported fibrosis improvement signals in MASH-related research. | Confirmation in larger phase 3 trials is needed. |
| Type 2 diabetes-related metabolic disease | Clinical-development context | Survodutide may affect weight and glucose-related metabolic outcomes. | It is not FDA-approved for diabetes. |
| General online weight loss | Unsafe / unapproved | Online sellers may market survodutide before approval. | Product quality, identity, sterility, dose, and safety may be unknown. |
| “Research use only” survodutide | Unsafe / unapproved | Research-use language is common in peptide markets. | It does not make the product approved, safe, or appropriate for human use. |
What does the research show?
Human evidence for obesity
Survodutide has human clinical evidence for weight loss.
A Lancet Diabetes & Endocrinology phase 2 trial evaluated survodutide in people with overweight or obesity and reported dose-dependent body-weight reduction.
Boehringer Ingelheim later announced phase 3 SYNCHRONIZE-1 results, stating that survodutide achieved significant weight loss of 16.6% in adults with obesity or overweight without type 2 diabetes. Reuters also reported that the Boehringer-Zealand drug led to 16.6% weight loss in a late-stage trial, compared with 3.2% for placebo.
The practical interpretation:
Survodutide has meaningful human clinical evidence for weight loss, but reported phase 3 success is not the same as FDA approval.
Human evidence for MASH
Survodutide is especially important because of its liver-disease research.
A New England Journal of Medicine phase 2 trial evaluated survodutide in adults with MASH and fibrosis. The PubMed summary describes a 48-week phase 2 trial in adults with biopsy-confirmed MASH and fibrosis stages F1 through F3.
Boehringer Ingelheim reported that survodutide showed improvement in liver fibrosis with no worsening of MASH in a large proportion of patients with F2 and F3 fibrosis.
The practical interpretation:
Survodutide may be more than an obesity drug candidate. Its dual glucagon/GLP-1 mechanism is being studied for liver-fat and MASH-related outcomes, but final approval and long-term liver outcomes remain unresolved.
Phase 3 development
Survodutide is in late-stage clinical development.
A 2024 PubMed-indexed rationale and design paper describes two multinational phase 3 trials investigating survodutide for obesity management in people with or without type 2 diabetes.
Boehringer Ingelheim’s SYNCHRONIZE program is designed to evaluate survodutide for obesity and related metabolic outcomes. However, trial success, press releases, and conference updates are not the same as FDA approval.
The practical interpretation:
Survodutide is one of the most important investigational dual glucagon/GLP-1 obesity drugs, but it remains unapproved until regulators review and approve it.
Evidence summary
| Claim | Evidence verdict | Explanation |
|---|---|---|
| “Survodutide is a dual glucagon/GLP-1 receptor agonist.” | Supported | Boehringer Ingelheim and Zealand Pharma describe it as a dual glucagon/GLP-1 receptor agonist. |
| “Survodutide causes weight loss.” | Supported by clinical-trial evidence | Phase 2 and reported phase 3 data show meaningful weight-loss effects. |
| “Survodutide treats MASH.” | Promising but investigational | Phase 2 data show MASH improvement signals, but regulatory approval is not established. |
| “Survodutide is FDA-approved.” | False | Survodutide is investigational and not FDA-approved. |
| “Survodutide is the same as semaglutide.” | False | Semaglutide is a GLP-1 receptor agonist; survodutide is a dual glucagon/GLP-1 receptor agonist. |
| “Survodutide is the same as tirzepatide.” | False | Tirzepatide targets GIP and GLP-1; survodutide targets glucagon and GLP-1. |
| “Survodutide is the same as retatrutide.” | False | Retatrutide targets GIP, GLP-1, and glucagon; survodutide targets glucagon and GLP-1. |
| “Research-use survodutide is safe if the seller claims purity.” | Unsupported | Online products may have unknown identity, purity, sterility, concentration, and safety. |
| “Survodutide is allowed for athletes.” | Unclear / verify | It was not found here as specifically named by WADA, but unapproved investigational drugs may create anti-doping risk. |
Is survodutide FDA-approved?
No. Survodutide is not FDA-approved.
Boehringer Ingelheim and Zealand Pharma describe survodutide as an investigational drug candidate. The company has reported phase 3 obesity results, but public trial results and press releases do not equal FDA approval.
The key distinction:
Survodutide has real clinical evidence, but there is no FDA-approved survodutide product for consumers.
Is survodutide legal?
Survodutide is not legally available as a normal FDA-approved prescription medication.
It may be available to eligible participants through legitimate clinical trials. It should not be treated as legal, safe, or approved just because an online seller offers it as a peptide, research chemical, or compounded product.
The blunt version:
If a website is selling survodutide directly to consumers, it is not selling an FDA-approved medication.
Is survodutide banned in sports?
I did not find survodutide specifically named on the WADA prohibited list in the sources reviewed here.
However, the WADA Prohibited List includes broad categories, including S0 non-approved substances. Because survodutide is investigational and not FDA-approved, athletes should not assume it is permitted.
The practical advice:
Athletes should check Global DRO, WADA, or USADA before using survodutide or any investigational metabolic drug. Online research-use products are especially high-risk.
Safety and side effects
Survodutide has promising clinical-trial data, but it is still being evaluated.
Common adverse effects in trials are generally gastrointestinal, similar to other incretin-based medications. These may include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Decreased appetite
- Abdominal discomfort
- Injection-site reactions
Important safety uncertainties include:
- Long-term safety
- Final approved dosing, if approved
- Final contraindications and warnings, if approved
- Risks in broader real-world populations
- Liver-related safety and efficacy outcomes over longer timeframes
- Product-quality risks from online sellers
- Dosing errors from self-mixed or unapproved products
- Counterfeit, contaminated, or mislabeled products
A serious evaluation of survodutide should separate clinical-trial survodutide from gray-market survodutide products.
Survodutide vs similar drugs and peptides
| Compound | Category | Main difference |
|---|---|---|
| Survodutide | Dual glucagon/GLP-1 receptor agonist | Investigational drug candidate studied for obesity and MASH. |
| Semaglutide | GLP-1 receptor agonist | FDA-approved under Ozempic, Wegovy, and Rybelsus for specific indications. |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | FDA-approved under Mounjaro and Zepbound for specific metabolic indications. |
| Retatrutide | Triple GIP/GLP-1/glucagon receptor agonist | Investigational triple agonist from Eli Lilly. |
| Cagrilintide | Long-acting amylin analog | Investigational amylin analog being developed for weight management. |
| BPC-157 | Experimental repair peptide | Not a metabolic incretin or glucagon drug. |
| Tesamorelin | GHRH analog | FDA-approved for HIV-associated abdominal lipodystrophy, not a GLP-1/glucagon agonist. |
The key distinction:
Survodutide is a dual glucagon/GLP-1 receptor agonist. It is not a GIP drug, amylin analog, tissue-repair peptide, or growth hormone secretagogue.
Why is survodutide sold as “research use only”?
Some online sellers may use “research use only” language to sell survodutide before approval. That is a red flag.
A serious reader should understand this distinction:
| Product type | What it means |
|---|---|
| Clinical-trial survodutide | Investigational drug used under controlled research conditions. |
| FDA-approved survodutide | Does not currently exist. |
| Compounded survodutide | Not the same as an FDA-approved medication and should be treated as high-risk. |
| Research-use survodutide | Not an FDA-approved consumer therapeutic product. |
| Online peptide survodutide | High risk for quality, sterility, dosing, identity, and legal problems. |
How to evaluate survodutide claims online
| Claim | What to verify |
|---|---|
| “FDA-approved survodutide” | False. Survodutide is not FDA-approved. |
| “Same as clinical-trial survodutide” | Clinical-trial products are controlled. Online peptide products may not be. |
| “Same as semaglutide” | False. Survodutide targets glucagon and GLP-1; semaglutide targets GLP-1. |
| “Same as tirzepatide” | False. Tirzepatide targets GIP and GLP-1; survodutide targets glucagon and GLP-1. |
| “No side effects” | False. Trials report adverse effects, especially gastrointestinal symptoms. |
| “Research use only” | This does not mean safe, legal, approved, or appropriate for human use. |
| “Safe for athletes” | Verify through WADA, USADA, or Global DRO. Do not assume investigational drugs are permitted. |
| “Cheap survodutide online” | High risk. Product identity, sterility, purity, dose, and safety may be unknown. |
Bottom line
Survodutide is an investigational once-weekly dual glucagon/GLP-1 receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma. It has meaningful clinical-trial evidence for weight loss and promising phase 2 evidence in MASH, but it is not FDA-approved and is not available as a normal prescription medication.
The most defensible conclusion is:
Survodutide is one of the most important investigational GLP-1/glucagon obesity and MASH drugs, but it should be treated as a clinical-stage medication, not a consumer peptide. Readers should avoid online survodutide, research-use survodutide, and gray-market products that are not part of legitimate clinical care or clinical trials.
FAQ
What is survodutide?
Survodutide is an investigational once-weekly injectable dual glucagon/GLP-1 receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma.
What does survodutide do?
Survodutide activates GLP-1 and glucagon receptor pathways. It is being studied for weight loss, appetite regulation, metabolic effects, and liver-related outcomes in MASH.
Is survodutide FDA-approved?
No. Survodutide is not FDA-approved. It is an investigational drug being studied in clinical trials.
Can doctors prescribe survodutide?
No, not as a normal FDA-approved prescription medication. Survodutide may be available only through legitimate clinical trials for eligible participants.
Does survodutide work for weight loss?
Clinical trials suggest survodutide can produce meaningful weight loss. Boehringer Ingelheim reported 16.6% weight loss in a phase 3 obesity trial, but survodutide remains investigational until regulatory approval is granted.
Does survodutide treat MASH?
A phase 2 trial showed promising MASH-related results, including improvement in MASH without worsening fibrosis. However, survodutide is not FDA-approved for MASH.
Is survodutide the same as semaglutide?
No. Semaglutide is a GLP-1 receptor agonist. Survodutide is a dual glucagon/GLP-1 receptor agonist.
Is survodutide the same as tirzepatide?
No. Tirzepatide targets GIP and GLP-1 receptors. Survodutide targets glucagon and GLP-1 receptors.
Is survodutide the same as retatrutide?
No. Retatrutide targets GIP, GLP-1, and glucagon receptors. Survodutide targets glucagon and GLP-1 receptors.
Is survodutide safe?
Survodutide has been studied in human clinical trials, but it is not FDA-approved and long-term safety is still being evaluated. Common side effects are generally gastrointestinal, and online products may add quality, sterility, identity, and dosing risks.
Is survodutide banned in sports?
I did not find survodutide specifically named on the WADA prohibited list in the sources reviewed here. However, because it is investigational and not FDA-approved, athletes should verify status through WADA, USADA, or Global DRO before use.
Why do sellers call survodutide “research use only”?
Sellers may use “research use only” language because survodutide is not FDA-approved for consumer therapeutic use. The phrase does not make the product safe, legal, approved, or clinically equivalent to trial-grade survodutide.
What is the biggest risk with survodutide?
The biggest risk is using an unapproved drug outside clinical trials or buying online survodutide with unknown quality, concentration, sterility, identity, and safety.
Sources
- Boehringer Ingelheim: Survodutide Obesity and Overweight Phase 3 Update
- Boehringer Ingelheim: SYNCHRONIZE-1 Phase 3 Obesity Trial Results
- Zealand Pharma: Survodutide Pipeline
- NEJM: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
- PubMed: A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
- Lancet Diabetes & Endocrinology: Glucagon and GLP-1 Receptor Dual Agonist Survodutide for Obesity
- PMC: Survodutide for Treatment of Obesity, Rationale and Design of Phase 3 Trials
- PubMed: Survodutide for Treatment of Obesity, Baseline Characteristics of Phase 3 Trials
- Reuters: Boehringer-Zealand Drug Leads to 16.6% Weight Loss in Late-Stage Trial
- WADA: Prohibited List
Frequently asked questions
What is survodutide?
Survodutide is an investigational once-weekly injectable dual glucagon/GLP-1 receptor agonist being developed by Boehringer Ingelheim and Zealand Pharma.
Is survodutide FDA-approved?
No. Survodutide is not FDA-approved. It is an investigational drug being studied in clinical trials.
Does survodutide work for weight loss?
Clinical trials suggest survodutide can produce meaningful weight loss. Boehringer Ingelheim reported 16.6% weight loss in a phase 3 obesity trial, but survodutide remains investigational until regulatory approval is granted.
Does survodutide treat MASH?
A phase 2 trial showed promising MASH-related results, including improvement in MASH without worsening fibrosis. However, survodutide is not FDA-approved for MASH.
Is survodutide the same as semaglutide?
No. Semaglutide is a GLP-1 receptor agonist. Survodutide is a dual glucagon/GLP-1 receptor agonist.
Is survodutide safe?
Survodutide has been studied in human clinical trials, but it is not FDA-approved and long-term safety is still being evaluated. Common side effects are generally gastrointestinal, and online products may add quality, sterility, identity, and dosing risks.
Sources
- [1]
- [2]
- [3]Zealand Pharma: Survodutide Pipeline
Developer
- [4]
- [5]
- [6]
- [7]PMC: Survodutide for Treatment of Obesity, Rationale and Design of Phase 3 Trials
Clinical Trial Design
- [8]
- [9]
- [10]WADA: Prohibited List
Anti Doping
Last updated May 9, 2026